Diabetologia publishes reports of clinical and experimental work on all aspects of diabetes research and related subjects, provided they have scientific merit and present important facts or new data. Invited Reviews and Editorials are also published. Rapid communications of results with immediate interest may also be considered for expedited publication. Mere confirmation of known facts will be accepted only in exceptional cases; the same applies to reports of experiments and observations having no positive outcome. The Editor in Chief will be pleased to consider for publication papers read at meetings of the European Association for the Study of Diabetes, provided that they meet the above requirements. Letters to the Editor commenting on previously published work in Diabetologia, and Workshop reports are also welcome. It should be noted that there are no page charges with the exception of Workshop reports.

Manuscripts (5 copies) should be sent to:
Professor C. Hellerström
Editor-in-Chief
Diabetologia
Department of Medical Cell Biology
Biomedicum, Box 571
S-75123 Uppsala
Sweden

Copyright
Submission of a manuscript implies: that the work described has not been published before (except in the form of an abstract); that it is not under consideration for publication elsewhere; that its publication has been approved by all co-authors, if any, as well as by the responsible authorities at the institute where the work has been carried out; that, if and when the manuscript is accepted for publication, the authors agree to automatic transfer of the copyright to the publisher and that the manuscript will not be published elsewhere in any language without the consent of the copyright holders.

All articles published in this journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article (e.g., as offprints), as well as all translation rights. No material published in this journal may be reproduced photographically or stored on microfilm, in electronic data bases, video disks, etc., without first obtaining written permission from the publisher.

The use of general descriptive names, trade names, trademarks, etc., in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

While the advice and information in this journal is believed to be true and accurate at the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Special regulations for photocopies in the USA. Photocopies may be made for personal or institutional use beyond the limitations stipulated under Section 107 or 108 of U.S. Copyright Law, provided a fee is paid. This fee is US$ 0.20 per page per copy, plus a basic fee of US$2.00 per article. All fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA, stating the ISSN 0012-186X, the volume, and the first and last page numbers of each article copied. The copyright owner's consent does not include copying for general distribution, promotion, new works, or resale. In these cases, specific written permission must first be obtained from the publisher.

This journal is included in the ADONIS service, whereby copies of individual articles can be printed out from compact discs (CD-ROM) on demand. To help people requesting articles from participating ADONIS centres we have developed the ADONIS Identification System which provides every article, etc., with a separate unique number. This ADONIS number can then be used to order a document. The number appears at the top left-hand corner of the first page of each article. An explanatory leaflet giving further details of the scheme is available from the publishers on request.

Subscription information
Volume 34 (12 issues) will appear in 1991. North America: Recommended annual subscription rate: approx. US $ 383.00, single issue price US $ 34.00; including carriage charges. Subscriptions are entered with prepayment only. Orders should be addressed to: Springer-Verlag New York Inc., Service Center Secaucus, 44 Hartz Way, Secaucus, NJ 07094, USA, Tel. (201) 348-4033, Telex O25125994, FAX (201) 348-4505.

All other countries: Recommended annual subscription rate: DM 528.00, plus carriage charges; (Federal Republic of Germany: DM 24.40 incl. value added tax; all other countries: DM 34.80 except for the following countries to which SAL delivery (Surface Airmail Lifted) is mandatory: Japan DM 99.60, India DM 70.80, Australia/New Zealand DM 115.20. Airmail delivery to all other countries is available upon request). Volume price: DM 528.00, single issue price: DM 52.80 plus carriage charges. Orders can either be placed via a bookdealer or sent directly to: Springer-Verlag, Heidelberger Platz 3, 1000 Berlin 33, FRG, Tel. (0) 30 / 8207-1, Telex 183319, FAX (0) 30/8214091. Members of the European Association for the Study of Diabetes, the American Diabetes Association and the International Diabetes Federation are entitled to reduced rates. Please inquire about them with the publisher.

Changes of address: Allow six weeks for all changes to become effective. All communications should include both old and new addresses with postal codes and should be accompanied by a mailing label from a recent issue.

Back volumes: Prices are available on request.

Microform: Microform editions are available from: University Microfilms International, 300 North Zeeb Road, Ann Arbor, MI 48106, USA.

Production
Springer-Verlag
Journal Production Department I
Postfach 105280
W-6900 Heidelberg 1
Federal Republic of Germany
Tel. 06221 /487-431, Telex 04-61723
FAX (0) 6221/487624

Responsibility for advertisements
Springer-Verlag GmbH & Co KG
Kerstin Schilling
Heidelberger Platz 3
1000 Berlin 33
Federal Republic of Germany
Tel. 030 / 8207-1-740, Telex 01-854119
FAX (0) 30/8207300

Printers
Druckhaus Beltz
W-6944 Hemsebach/Bergstraße
Federal Republic of Germany
© Springer-Verlag Berlin Heidelberg 1991
Springer-Verlag GmbH & Co KG
1000 Berlin 33, Federal Republic of Germany
Printed in Germany
Contents

Outcome of pancreatic transplantation

M. Olausson, G. Nyberg, G. Nordén, B. Frisk, L. Hedman
Outcome of pancreas transplantations in Göteborg, Sweden 1985–1990 S 1

A. Königsrainer, W. Steurer, C. Aichberger, R. Gassner, Th. Schmid, R. Margreiter
Pancreatic transplantation with delayed duct occlusion versus bladder drainage: long-term results S 4

X. Martin, N. Lefrancois, J.M. Marechal, A. Gelet, J.L. Viguier, J.M. Dubernard
Pancreas transplantation in Lyon: overall results S 8

Pancreas and kidney transplantation: the San Raffaele Hospital, (Milan, Italy) experience S 11

W.-D. Ilner, D. Abendroth, J. Nusser, R. Landgraf, W. Land
Long-term results in pancreatic transplantation with special emphasis on the use of prolamine S 14

G. Hillebrand, W.-D. Ilner, D. Abendroth, H. Schneeberger, I. Petry, S. Schleibner, R. Landgraf, W. Land
Outcome of renal grafts after simultaneous kidney/pancreas transplantation S 16

I.B. Brekke
Indications and results of pancreatic transplantation: the Oslo experience 1983–1990 S 18

G. Tydén, A. Tibell, J. Bolinder, J. Östman, C.-G. Groth
The Stockholm experience with pancreatic transplantation using enteroic exocrine diversion S 21

U.T. Hopt, M. Büsing, W.D. Schareck, H.D. Becker
The bladder drainage technique in pancreas transplantation: the Tübingen experience S 24

D.E.R. Sutherland
Report from the International Pancreas Transplant Registry S 28

Metabolic and hormonal control

E. Esmatjes, L. Fernández-Cruz, M.J. Ricart, R. Casamitjana, M.A. López-Boado, E. Astudillo
Metabolic characteristics in patients with long-term pancreas graft with systemic or portal venous drainage S 40

G. Nyberg, G. Fager, L. Mjörnstedt, M. Olausson
Metabolic risk factors for cardiovascular disease in pancreas and kidney transplant recipients S 44

Long-term follow-up of glycaemic control and parameters of lipid transport after pancreas transplantation S 47

Metabolic control after kidney and pancreas transplantation: whole series results and effects of segmental duct obstruction versus whole pancreas with bladder diversion technique S 51

A. Secchi, S. Martinenghi, R. Caldara, E. La Rocca, V. Di Carlo, G. Pozza
First peak insulin release after intravenous glucose and arginine is maintained for up to 3 years after segmental pancreas transplantation S 53

R. Landgraf, J. Nusser, R.L. Riepl, F. Fiedler, W.-D. Illner, D. Abendroth, W. Land
Metabolic and hormonal studies of Type 1 (insulin-dependent) diabetic patients after successful pancreas and kidney transplantation S 61

Long-term metabolic control in recipients of combined pancreas and kidney transplants S 68

F. Saudek, T. Pelikánová, V. Bartoš, I. Reneltová, L. Kazdová, J. Kovář, L. Karasová
Insulin action and insulin binding following pancreas transplantation S 71

J. Bolinder, G. Tydén, A. Tibell, C.-G. Groth, J. Östmann
Long-term metabolic control after pancreatic transplantation with enteric exocrine diversion S 76

Consequences of systemic venous drainage and denervation of heterotopic pancreatic transplants for insulin/C-peptide profiles in the basal state and after oral glucose  S 81

Retinopathy
A. Königsrainer, K. Miller, W. Steurer, G. Kieselbach, C. Aichberger, D. Öfner, R. Margreiter
Does pancreas transplantation influence the course of diabetic retinopathy?  S 86

Ophthalmological follow-up of Type 1 (insulin-dependent) diabetic patients after kidney and pancreas transplantation  S 89

F. Bandello, C. Vigano, A. Secchi, S. Martinenghi, R. Caldara, V. Di Carlo, G. Pozza, R. Brancato
Effect of pancreas transplantation on diabetic retinopathy: a 20-case report  S 92

A. Scheider, E. Meyer-Schwickerath, J. Nusser, W. Land, R. Landgraf
Diabetic retinopathy and pancreas transplantation: a 3-year follow-up  S 95

Neuropathy
C. Vial, X. Martin, N. Lefrancois, J.M. Dubernard, F. Chauvin, B. Bady
Sequential electrodiagnostic evaluation of diabetic neuropathy after combined pancreatic and renal transplantation  S 100

Neurophysiological study of the effect of combined kidney and pancreas transplantation on diabetic neuropathy: a 2-year follow-up evaluation  S 103

X. Navarro, W.R. Kennedy, D.E.R. Sutherland
Autonomic neuropathy and survival in diabetes mellitus: effects of pancreas transplantation  S 108

W. Müller-Felber, R. Landgraf, St. Wagner, N. Mair, J. Nusser, M.M.C. Landgraf-Leurs, A. Abendroth, W.-D. Illner, W. Land
Follow-up of sensory-motor polyneuropathy in Type 1 (insulin-dependent) diabetic subjects after simultaneous pancreas and kidney transplantation and after graft rejection  S 113

Effect of pancreatic and/or renal transplantation on diabetic autonomic neuropathy  S 118

Macro- and microcirculation
G. Nyberg, O. Bech-Hanssen, M. Olausson, I. Wallentin
Echocardiographic findings in kidney transplanted Type 1 (insulin-dependent) diabetic patients with and without a pancreas transplant  S 10

D. Abendroth, J. Schmand, R. Landgraf, W.-D. Illner, W. Land
Diabetic microangiopathy in Type 1 (insulin-dependent) diabetic patients after successful pancreatic and kidney or solitary kidney transplantation  S 108

G. Jörneskog, G. Tydén, J. Bolinder, B. Fagrell
Skin microvascular reactivity in fingers of diabetic patients after combined kidney and pancreas transplantation  S 113

Quality of life
P.S. Zehr, F.K. Milde, L.K. Hart, R.J. Corry
Pancreas transplantation: assessing secondary complications and life quality  S 120

A. Secchi, V. Di Carlo, S. Martinenghi, E. La Rocca, R. Caldara, D. Spotti, G. Slaviero, C. Staudacher, G. Ferrari, G. Pozza
Effect of pancreas transplantation on life expectancy, kidney function and quality of life in uraemic Type 1 (insulin-dependent) diabetic patients  S 120

C.L. Zehrer, C.R. Gross
Quality of life of pancreas transplant recipients  S 130

Quality of life in Type 1 (insulin-dependent) diabetic patients prior to and after pancreas and kidney transplantation in relation to organ function  S 130

Ö.H. Bentdal, P. Fauchald, I.B. Brekke, H. Holdaas, A. Hartmann
Rehabilitation and quality of life in diabetic patients after successful pancreas-kidney transplantation  S 130
Outcome of renal grafts after simultaneous kidney/pancreas transplantation

G. Hillebrand, W.-D. Illner, D. Abendroth, H. Schneeberger, I. Petry, S. Schleibner, R. Landgraf and W. Land

Summary. Nineteen patients with endstage renal failure due to Type 1 (insulin-dependent) diabetes mellitus received simultaneous pancreas/kidney transplants using bladder drainage technique. Another group of 25 Type 1 diabetic patients received pancreas/kidney transplants by the duct occlusion technique. We observed a higher incidence of rejection episodes in the patients of the bladder drainage group than those in the duct occlusion group, 14 of 19 patients (74%) vs 7 of 25 (28%) respectively. Anti CD3 antibodies (Orthoclone^, OKT3) as a part of induction treatment was used more often in the bladder drainage group (58%) than in the control group (20%).

Key words: Pancreas/kidney transplantation - Diabetes mellitus - Bladder drainage technique - Renal rejection episode

Introduction

In recent years, techniques and results in pancreas transplants have been remarkably improved, although surgical techniques and patient selections are still controversial, especially with respect to long-term results and reversibility of late diabetic complications.

In our first series of simultaneous kidney/pancreas transplants, relatively poor long-term results of the renal graft were observed when using the duct occlusion technique (Castro 1986, Hillebrand 1987). After modifying the immunosuppressive regimen and the concomitant therapy in the early postoperative phase, the prognosis for the renal graft was improved to the range of kidney transplantation (5-year graft survival rate of 56%). Details are described separately in this issue (Illner 1991).

In January 1989 we introduced the bladder drainage technique for pancreas grafting at our centre. In the following we report on our experience with this altered surgical method regarding the kidney graft.

Subjects and methods

In Group 1 (n = 25 patients) simultaneous transplantation was carried out using the duct occlusion technique. The operations were performed between June 1987 and March 1990 prior to changing methods. Group 2 (n = 19 patients) also received pancreas/kidney transplants but using the bladder drainage technique. Both groups were comparable with respect to HLA mismatches, preexistent cytotoxic antibodies, age, duration of Type 1 (insulin-dependent) diabetes mellitus and regular dialysis treatment (continuous ambulatory peritoneal dialysis CAPD/hemodialysis). There were slight differences in cold ischaemia time (Group 1:7.5 h, Group 2:13.8 h) as well as in sex distribution (male/female) (Group 1:10/15, Group 2 16/3). All patients were treated with a quadruple drug induction therapy consisting of cyclosporin, azathioprin, steroids and polyclonal sera (antilymphocyte globulin ALG or antithymocyte globulin ATG) or monoclonal serum anti CD3 antibodies Orthoclone^R OKT3. We evaluated incidence of rejection crises, actuarial 2-year kidney graft survival and patient survival.

Results

Rejection episodes were observed in 7 of 25 patients (28%) in Group 1, and in 14 of 19 patients (74%), in Group 2 (p<0.05 chi-square test). Steroid resistant rejection crises occurred six times in Group 1 and ten times in Group 2, which necessitated therapy with ALG, ATG or OKT3. Three renal grafts were lost in Group 1, 5 in Group 2, which necessitated therapy with ALG, ATG or OKT3. Three renal grafts were lost in Group 1, 5 in Group 2. Reasons for graft function loss were in Group 1: 2 patients' death, 1 chronic rejection; in Group 2: 3 acute, 2 chronic rejections.

The 2-year actuarial renal graft survival rate was calculated according to the Kaplan Mayer formula and showed better results in Group 1 83% (duct occlusion) than in Group 2 66% (bladder drainage).
Discussion

In our first series of simultaneous pancreas/kidney transplantation using the bladder drainage technique, 19 patients had a significant higher incidence of renal rejection episodes as well as an unfavourable 2-year renal graft survival in comparison to a historical control group with duct occlusion. This is in contrast to the results of other groups, which are published in this issue. Re-evaluation of the two patient groups showed - beside the above-mentioned differences in cold ischaemia time and sex distribution - a higher incidence in post-operative acute renal failure (Group 1 0%; Group 2 11%), and a frequent use of OKT3 as a part of the induction protocol (Group 1 20%; Group 2 58%); although differences in the efficacy between ALG vs OKT3 were not described by others (Knechtle 1991).

References


Dr. G. Hillebrand
Nephrology Department, Med. Klinik I,
Klinikum Grosshadern, University of Munich
P.O. Box 70 12 60
8000 Munich 70, F.R.G.
Aanstoot, H.-J. 388, A98
Abdel-Halim, S.M. 302, A76
Abendroth, D. 195, A49
Abinader, J. 627, A157
Abu, E.A. 508, A128
Adams, J.E. 155, A39
Adelantado, J.M. 797, A200
Adezati, L. 262, A66
Adlerberth, A. 276, A70
Adojaan, B. 258, A65
Adoyan, B. 706, A177
Ammalà, C. 250, A63
Ammalà, C. 342, A86
Ammalà, C. 346, A87
Ammalà, C. 350, A88
Aerts, L. 369, A93
Agardh, C.-D. 746, A187
Agius, L. 125, A32
Ahmed, S. 468, A118
Ahonen, P.J. 234, A59
Ahrén, B. 17, A5
Ahrén, B. 94, A24
Ahrén, B. 357, A90
Ahrén, B. 358, A90
Ahrén, B. 381, A96
Aimone, M. 592, A149
Aitchison, M. 622, A156
Aimone, E. 210, A53
Ammon, H.P.T. 353, A89
Ammon, H.P.T. 252, A64
Amoretti, R. 112, A29
Amundson, W.L. 369, A93
Andersen, P. 568, A143
Andersen, P. 553, A139
Andersen, P. 548, A138
Andersen, P. 542, A136
Andersen, L. 725, A182
Andersen, P. 121, A31
Andersen, P. 548, A138
Andersen, P. 553, A139
Andersen, P. 568, A143
Andersen, P.H. 8, A2
Andersen, P.H. 472, A119
Andersson, A. 299, A75
Andreetti, D. 112, A29
Andreetti, D. 210, A53
Andreassen, S. 732, A184
Andrejewskaja, S. 679, A170
Anfossi, G. 451, A113
Anfossi, G. 453, A114
Anfossi, G. 686, A172
Angel, J. 7, A2
Angelico, M.C. 796, A200
Angles-Cano, E. 555, A139
Ania-Lahuerta, M.A. 198, A50
Anichini, R. 524, A132
Anichini, R. 537, A135
Anselmo, J. 514, A129
Appel, M. 309, A78
Aranyi, Z. 645, A162
Arar, N. 445, A112
Arden, S.D. 225, A57
Arden, S.D. 366, A92
Arend, J.A.C.J. den 637, A160
Ariza, Z. 765, A192
Arkvel, E.C. van 293, A74
Arkhammar, P. 351, A88
Armengol, P. 480, A121
Arnaud, O. 488, A123
Arner, P. 506, A127
Arner, P. 695, A174
Arnoux, D. 555, A139
Arnqvis, H.J. 53, A14
Arnqvis, H.J. 54, A14
Arrieta, F.J. 479, A120
Arrieta, F.J. 500, A126
Arrieta, F.J. 504, A127
Arrol, S. 27, A7
Arrol, S. 534, A134
Artioli, M.G. 74, A19
Artioli, M.G. 239, A60
Asai, J. 170, A43
Asfari, M. 367, A92
Ashcroft, F.M. 349, A88
Ashcroft, F.M. 352, A89
Ashcroft, S.J.H. 219, A55
Ashcroft, S.J.H. 249, A63
Ashcroft, S.J.H. 326, A82
Aslam, N. 458, A115
Asscheri, F.A. Van 369, B13
Asscheri, F.A. van 503, A126
Assmacopoulos-Jeannet, F. 323, A81
Astbury, N.J. 590, A148
Atkinson, A.B. 490, A123
Atlan, C. 716, A180
Atlan-Gepner, C. 311, A78
Attalah, M. 542, A136
Attali, J.R. 294, A74
Attali, J.R. 542, A136
Attali, J.R. 662, A166
Audi, L. 528, A133
Augustin, P. 539, A180
Auinger, M. 618, A155
Aussieker, S. 562, A141
Auzan, C. 103, A26
Avogaro, A. 510, A128
Azerhad, R. 7, A2
Azevedo, M.S. 647, A162
Baba, S. 209, A53
Baba, T. 15, A4
Bacić, D. 566, A142
Bacić, D. 584, A147
Bacić, D. 724, A182
Babicheva, E.I. 81, A21
Bach, J.F. 208, A53
Bachschwöl, S. 518, A130
Badenkoop, C. 410, A103
Badenoch, D.F. 613, A154
Bärmeyer, H. 69, A18
Bärmeyer, H. 390, A98
Bagazgoitia, J. 583, A146
Bagracyak, N. 714, A179
Bailbe, D. 336, A85
Bailley, C.J. 115, A29
Baille, K.E. 26, A7
Bailyes, E.M. 214, A54
Bailyes, E.M. 225, A57
Bailyes, E.M. 368, A93
Bain, S.C. 413, A104
Baird, H.R. 37, A10
Baird, J.D. 676, A170
Baird, J.D. 677, A170
Bak, J.F. 8, A2
Bak, J.F. 235, A59
Bak, J.F. 474, A119
Balaban, S. 63, A16
Balducci, S. 436, A110
Ballago-Dordov, G. 645, A162
Ballehe, E. van 531, A133
Bang, L. 645, A162
Balsano, F. 611, A153
Balsano, F. 635, A159
Balsells, M. 797, A200
Balsells, M. 798, A200
Band, A. 288, A73
Banford, C. 594, A149
Bang, P. 773, A194
Bangstod, H.-J. 90, A23
Bangstotd, H.-J. 172, A44
Banovic, D. 296, A75
Baranyi, E. 800, A201
Barceló, J. 762, A191
Bardet, S. 716, A180
Barilli, A.L. 774, A194
Barkai, L. 628, A158
Barnett, A.H. 151, A38
Barnett, A.H. 256, A65
Barnett, A.H. 259, A65
Barnett, A.H. 401, A136
Bennett, A.H. 402, A136
Bennett, A.H. 403, A136
Bennett, A.H. 413, A104
Bennett, A.H. 415, A104
Baroni, M.G. 239, A60
Barri, F.J. 504, A127
Barri, F.J. 488, A123
Barri, F.J. 505, A127
Barri, E. 56, A14
Barri, T. 94, A24
Bartolomei, G.C. 246, A62
Bartolomei, G.C. 524, A132
Barzilai, D. 63, A16
Barzson, T. 73, A19
Barzson, T. 271, A68
Barzakos, J. 511, A128
Basta, G. 674, A169
Basdev, H. 288, A73
Basdev, H. 321, A81
Batt, E. 56, A14
Batt, T. 94, A24
Battolomei, G.C. 246, A62
A219

Zachariadis, D. 240, A61
Zaidi, K.F. 247, A62
Zamaklar, M. 296, A75
Zamaklar, M. 673, A169
Zambelli, L. 567, A142
Zancanaro, C. 469, A118
Zambelli, L. 567, A142
Zancanaro, C. 469, A118
Zavaroni, I. 75, A19
Zecchi, A. 262, A66
Zekorn, T. 675, A169
Zellenrath, P. 598, A150
Zenere, M. 74, A19
Zenere, M. 239, A60
Zenobi, P.D. 771, A193
Zenobi, P.D. 772, A194
Zenobi, P.D. 772, A194
Zent, M.G. 567, A142
Zerbini, G. 91, A23
Zerbini, G. 268, A68
Zerbini, G. 532, A134
Zerbini, G. 538, A135
Zhang, A. 360, A91
Zhang, F. 416, A105
Zhang, Z. 460, A116
Ziegler, A.G. 223, A56
Ziegler, A.G. 408, A103
Ziegler, A.G. 758, A190
Ziegler, B. 315, A79
Ziegler, B. 383, A96
Ziegler, D. 146, A37
Ziegler, D. 233, A59
Ziegler, M. 314, A79
Ziegler, M. 315, A79
Ziegler, M. 319, A80
Ziegler, M. 383, A96
Ziegler, O. 455, A114
Ziegler, R. 175, A44
Zierath, J.R. 43, A1 A1
Zimmermann, U. 675, A169
Zink, S. 139, A35
Ziora, D. 29, A8
Zolli, M. 510, A128
Zoppitelli, P. 210, A53
Zoppitelli, P. 317, A80
Zoppo, A. 91, A23
Zoppo, A. 551, A138
Zouali, H. 393, A99
Zühlke, H. 313, A79
Zumsteg, U. 377, A95
Zweers, E.J.K. 791, A198
Zwick, H. 618, A155